Biologic therapies for inflammatory eye disease

Lyndell Lim, Eric B. Suhler, Justine R. Smith

Research output: Contribution to journalReview articlepeer-review

84 Scopus citations


The era of biologic medical therapies provides new options for patients with treatment-resistant inflammatory eye disease. In this review, the authors summarize current published experience in a rapidly progressing clinical field, including the use of biologics, such as the tumour necrosis factor blockers, daclizumab and rituximab, and related agents, interferons and intravenous immunoglobulin, for the treatment of uveitis, scleritis and orbital inflammation. Reports of dramatic recoveries in patients with recalcitrant ocular inflammation who have received such therapies must be balanced against the high cost of biologics and the potential for serious, and at times unanticipated, complications of this treatment.

Original languageEnglish (US)
Pages (from-to)365-374
Number of pages10
JournalClinical and Experimental Ophthalmology
Issue number4
StatePublished - May 1 2006


  • Biologic
  • Immunosuppression
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Biologic therapies for inflammatory eye disease'. Together they form a unique fingerprint.

Cite this